

Attapulgate

1 Nonproprietary Names

BP: Attapulgate

2 Synonyms

Actapulgate; *Attaclay*; *Attacote*; *Attagel*; attapulgis; palygorskite; palygorskite; *Pharmsorb Regular*.

3 Chemical Name and CAS Registry Number

Attapulgate [12174-11-7]

4 Empirical Formula Molecular Weight

Attapulgate is a purified native hydrated magnesium aluminum silicate consisting of the clay mineral palygorskite, with the empirical formula $\text{Mg}(\text{Al}_{0.5-1}\text{Fe}_{0-0.5})\text{Si}_4\text{O}_{10}(\text{OH})\cdot 4\text{H}_2\text{O}$.

5 Structural Formula

See Section 4.

6 Functional Category

Adsorbent.

7 Applications in Pharmaceutical Formulation or Technology

Attapulgate is widely used as an adsorbent in solid dosage forms. Colloidal clays (such as attapulgate) absorb considerable amounts of water to form gels and in concentrations of 2–5% w/v usually form oil-in-water emulsions. Activated attapulgate, which is attapulgate that has been carefully heated to increase its absorptive capacity, is used therapeutically as an adjunct in the management of diarrhea.

8 Description

Attapulgate occurs as a light cream colored, very fine powder. Particle size ranges depend on the grade and manufacturer.

9 Pharmacopeial Specifications

See Table I. See also Section 17.

10 Typical Properties

Acidity/alkalinity: pH = 9.5 (5% w/v aqueous suspension)

Angle of repose: 37.2–45.2°⁽¹⁾

Density: 2.2 g/cm³

Density (tapped): 0.33 g/cm³ ⁽¹⁾

Flowability: 20.9–29.6% (Carr compressibility index)⁽¹⁾

Particle size distribution:

<2 μm in size for powder

2–5 μm in size for aggregate.⁽¹⁾

Table I: Pharmacopeial specifications for attapulgate.

Test	BP 2001
Identification	+
Character	+
Acidity or alkalinity (5% w/v aqueous suspension)	7.0–9.5
Adsorptive capacity	5–14%
Arsenic	≤ 8 ppm
Heavy metals	≤ 20 ppm
Acid-insoluble matter	≤ 12.5%
Water-soluble matter	≤ 0.5%
Loss on drying	≤ 17.0%
Loss on ignition	15.0–27.0%

11 Stability and Storage Conditions

Attapulgate can adsorb water. It should be stored in an airtight container in a cool, dry, location.

12 Incompatibilities

Attapulgate may decrease the bioavailability of some drugs such as loperamide⁽²⁾ and riboflavin.⁽³⁾ Oxidation of hydrocortisone is increased in the presence of attapulgate.⁽⁴⁾

13 Method of Manufacture

Attapulgate occurs naturally as the mineral palygorskite.

14 Safety

Attapulgate is widely used in pharmaceutical formulations and is generally regarded as an essentially nontoxic and nonirritant material. It is not absorbed following oral administration. In oral preparations, activated attapulgate up to 9 g is used in daily divided doses as an adjunct in the management of diarrhea.⁽⁵⁾

LD₅₀ (rat, IP): 0.34 g/kg

15 Handling Precautions

Observe normal precautions appropriate to the circumstances and quantity of material handled. Eye protection, gloves, and a dust mask are recommended. Attapulgate should be handled in a well-ventilated environment and dust generation should be minimized. When heated to decomposition, attapulgate emits acrid smoke and irritating fumes.

16 Regulatory Status

Included in nonparenteral medicines licensed in a number of countries worldwide including the UK and US.

17 Related Substances

Activated attapulgitte; magnesium aluminum silicate.

Activated attapulgitte

Comments: activated attapulgitte is a processed native magnesium aluminum silicate that has been carefully heated to increase its adsorptive capacity. Monographs for activated attapulgitte are included in the BP 2001, USP 25, and other pharmacopeias. The USP 25 also includes a monograph for colloidal activated attapulgitte.

18 Comments

—

19 Specific References

- 1 Viseras C, López-Galindo A. Characteristics of pharmaceutical grade phyllosilicate powders. *Pharm Dev Technol* 2000; 5(1): 47–52.
- 2 Mboya SA, Bhargava HN. Adsorption and desorption of loperamide hydrochloride by activated attapulgitte. *Am J Health Syst Pharm* 1995; 52: 2816–2818.

- 3 Khalil SAH, Mortada LM, Shams-Eldeen MA, El-Khawas MM. Effect of attapulgitte on the bioavailability of a model low dose drug (riboflavine) in humans. *Drug Dev Ind Pharm* 1987; 13: 369–382.
- 4 Cornejo J, Hernosin MC, White JL, *et al.* Oxidative degradation of hydrocortisone in the presence of attapulgitte. *J Pharm Sci* 1980; 69: 945–948.
- 5 Sweetman SC, ed. *Martindale: the Complete Drug Reference*, 33rd edn. London: Pharmaceutical Press, 2002: 1212.

20 General References

- Anonymous. The silicates: attapulgitte, kaolin, kieselguhr, magnesium trisilicate, pumice, talc. *Int J Pharm Compound* 1998; 2(2): 162–163.
- Viseras C, Yebra A, López-Galindo A. Characteristics of pharmaceutical grade phyllosilicate compacts. *Pharm Dev Technol* 2000; 5(1): 53–58.

21 Author

A Palmieri.

22 Date of Revision

29 July 2002.